Aim: to study the effectiveness of ranolazine in complex therapy in chronic coronary syndrome, chronic obstructive pulmonary disease and obese patients. Object and methods of the study. Participants (n=30) were evenly divided into two groups: 1st (control), in which patients received standard therapy, and 2nd (main), in which patients received ranolazine at a dose of 500 mg 2 times a day for 1 month additional to complex therapy. The control group consisted of 20 healthy individuals. Results. After treatment, the level of total cholesterol and atherogenic index was lower by 8.6% (p<0.05) and by 14.5% (p<0.05) in the main group compared to control. It was found a decrease by 5.9% (p<0.05) of NT-proBNP level, an increase by 21.6% (p<0.05) the content of stable metabolites of nitric oxide (NO), by 32.6% (p<0.05) NO₃, a decrease by 3.6% (p<0.05) the level of endothelin-1 in the second patients’ group. Conclusion. The use of ranolazine in complex therapy improves the plasma lipid spectrum (decrease total cholesterol and atherogenic index levels), endothelial function (increase the content of stable metabolites NO, NO₃, decrease endothelin-1), and reduces NT-proBNP in chronic coronary syndrome, chronic obstructive pulmonary disease, and obese patients.